Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
Adding gemcitabine to cisplatin did not improve disease-free survival in bladder cancer patients
A Phase II randomized trial in 69 patients with pT2-pT3N0M0 muscle-invasive bladder cancer found similar 2-year disease-free survival (58.3%…
Adding gemcitabine to cisplatin radiotherapy did not improve disease-free survival for bladder cancer patients, with similar two-year rates …
Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC
Small study tests new drug combination with radiation for limited-stage small cell lung cancer
A Phase I dose-finding trial in 9 treatment-naïve patients with limited-stage small cell lung cancer established amrubicin 25 mg/m² plus cis…
A new drug combination with radiation showed a 100% response rate and 64.8% five-year survival in early-stage small cell lung cancer patient…
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …
Platinum-based intraperitoneal chemotherapy improves disease-free survival after curative CRC resection
Study reviews chemotherapy method for colorectal cancer after surgery
A meta-analysis of 1,264 adults receiving curative colorectal cancer resection found platinum-based prophylactic intraperitoneal chemotherap…
Giving chemotherapy directly into the abdomen after colorectal cancer surgery helped patients stay cancer-free longer without adding serious…
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…
Triapine Added to Cisplatin and Radiation for Cervical/Vaginal Cancer: Phase III Results
Could a new drug boost survival for women with advanced cervical and vaginal cancers?
Phase III trial evaluates triapine with cisplatin and radiation vs. standard treatment for advanced cervical and vaginal cancers.
A new drug called triapine may help women with advanced cervical and vaginal cancers live longer when added to standard radiation and chemot…